Tumor markers are associated with rapidly progressive interstitial lung disease in adult-dermatomyositis

[1]  J. Callen,et al.  Corrigendum to: A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies , 2021, Rheumatology.

[2]  M. Kuwana,et al.  Antiviral proinflammatory phenotype of monocytes in anti-MDA5 antibody-associated interstitial lung disease. , 2021, Rheumatology.

[3]  Q. Luo,et al.  Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study. , 2021, Rheumatology.

[4]  J. Callen,et al.  A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies , 2021, Rheumatology.

[5]  Changyi Yang,et al.  Elevated carcinoembryonic antigen predicts rapidly progressive interstitial lung disease in clinically amyopathic dermatomyositis. , 2021, Rheumatology.

[6]  Jing He,et al.  Predictors and Mortality of Rapidly Progressive Interstitial Lung Disease in Patients With Idiopathic Inflammatory Myopathy: A Series of 474 Patients , 2020, Frontiers in Medicine.

[7]  Xiaofeng Li,et al.  Increases in tumor markers are associated with primary Sjögren’s syndrome-associated interstitial lung disease , 2020, Therapeutic advances in chronic disease.

[8]  V. Werth,et al.  Malignancy in Dermatomyositis: A Retrospective Study of 201 Patients Seen at the University of Pennsylvania. , 2020, Journal of the American Academy of Dermatology.

[9]  M. Strek,et al.  Recognition and Management of Myositis-Associated Rapidly Progressive Interstitial Lung Disease. , 2020, Chest.

[10]  M. Kusaoi,et al.  Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy. , 2020, Rheumatology.

[11]  C. Bao,et al.  Serum KL‐6 level is a prognostic marker in patients with anti‐MDA5 antibody‐positive dermatomyositis associated with interstitial lung disease , 2019, Journal of clinical laboratory analysis.

[12]  E. Lee,et al.  Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease , 2019, Arthritis Research & Therapy.

[13]  Y. Ishikawa,et al.  Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis , 2018, Arthritis Research & Therapy.

[14]  Der-Yuan Chen,et al.  The clinical application of tumor markers in the screening of malignancies and interstitial lung disease of dermatomyositis/polymyositis patients: A retrospective study , 2018, SAGE open medicine.

[15]  N. Resseguier,et al.  Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease , 2018, Rheumatology International.

[16]  K. Hirata,et al.  Correlation between disease activity and serum ferritin in clinically amyopathic dermatomyositis with rapidly-progressive interstitial lung disease: a case report , 2018, BMC Research Notes.

[17]  Y. Kirino,et al.  The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease , 2018, Arthritis Research & Therapy.

[18]  R. Hubbard,et al.  An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. , 2017, The Lancet. Respiratory medicine.

[19]  P. Lachenbruch,et al.  2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups , 2017, Arthritis & rheumatology.

[20]  A. Baibergenova,et al.  Risk of Malignancy in Dermatomyositis and Polymyositis , 2017, Journal of cutaneous medicine and surgery.

[21]  B. Liang,et al.  Tumour markers in rheumatoid arthritis-associated interstitial lung disease. , 2016, Clinical and experimental rheumatology.

[22]  A. Ryan,et al.  Macrophage Akt1 Kinase-Mediated Mitophagy Modulates Apoptosis Resistance and Pulmonary Fibrosis. , 2016, Immunity.

[23]  S. Takezaki,et al.  Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. , 2015, Rheumatology.

[24]  Yuan Liu,et al.  Interstitial lung disease in clinically amyopathic dermatomyositis (CADM) patients: a retrospective study of 41 Chinese Han patients , 2013, Rheumatology International.

[25]  A. Morice,et al.  Serum carcinoembryonic antigen correlates with severity of idiopathic pulmonary fibrosis , 2012, Respirology.

[26]  K. smoyer-Tomic,et al.  Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis , 2012, BMC Musculoskeletal Disorders.

[27]  M. Kramer,et al.  The significance of elevated tumor markers among patients with idiopathic pulmonary fibrosis before and after lung transplantation. , 2012, Chest.

[28]  L. Mouthon,et al.  Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. , 2011, Arthritis and rheumatism.

[29]  A. Reed,et al.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis , 2011, Nature Reviews Rheumatology.

[30]  Takeshi Johkoh,et al.  American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .

[31]  J. Grutters,et al.  CA 15-3 as an alternative marker for KL-6 in fibrotic lung diseases. , 2010, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[32]  H. Yamanaka,et al.  Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. , 2010, Rheumatology.

[33]  K. Eguchi,et al.  Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. , 2009, Chest.

[34]  J. Szántó,et al.  Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices. , 2008, Journal of autoimmunity.

[35]  P. Szodoray,et al.  Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. , 2008, The Journal of rheumatology.

[36]  Yue-ying Gu,et al.  Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study , 2007, Clinical Rheumatology.

[37]  H. Satoh,et al.  Increased levels of KL‐6 and subsequent mortality in patients with interstitial lung diseases , 2006, Journal of internal medicine.

[38]  M. Nakashima,et al.  Serum levels of KL‐6 are positively correlated with those of CA15‐3 in patients with interstitial pneumonia associated with collagen diseases , 2006, Respirology.

[39]  J. Roselló-Catafau,et al.  Activation of alveolar macrophages in lung injury associated with experimental acute pancreatitis is mediated by the liver. , 1999, Annals of surgery.

[40]  H. Natori,et al.  Carcinoembryonic antigen in bronchoalveolar lavage fluid in patients with idiopathic pulmonary fibrosis. , 1985, Japanese journal of medicine.